Treatment of Autoimmune Metaplastic Atrophic Gastritis with Active H. pylori Infection and Penicillin Allergy
Clinical Scenario
This protocol addresses patients with autoimmune gastritis (AIG) who have a concurrent active Helicobacter pylori infection and a documented true penicillin allergy. The allergy directly limits which eradication regimens are appropriate, narrowing the safe first-line options for this population.
Why This Combination Requires a Specific Approach
Active H. pylori infection in the setting of autoimmune gastritis carries implications for cancer risk and can worsen nutritional deficiencies, making eradication a priority. A confirmed penicillin allergy, however, rules out several otherwise recommended regimens. Among the standard options for treatment-naive patients, only one regimen remains suitable when penicillin allergy is present.
Treatment Approach (Partial Overview)
The recommended first-line approach for this scenario is an optimized bismuth-based quadruple eradication therapy. The complete protocol — including the specific agents, dosing schedule, and sequencing — is available in the structured regimen below.
Treatment Goals
Eradication of H. pylori must be confirmed by a negative test of cure — urea breath test, fecal antigen test, or biopsy-based test — performed at least 4 weeks after completing therapy.
References
- Given the implications of potentially undiagnosed H. pylori infection for cancer risk and exacerbating nutritional deficiencies (e.g., iron deficiency), H. pylori testing and treatment in all patients diagnosed with AIG are recommended.
- Of the recommended and suggested options for treatment-naive patients, only optimized BQT is suitable for patients with a true penicillin allergy.
- In treatment-naive patients with H. pylori infection, optimized BQT is recommended as a first-line treatment option (strong recommendation; moderate quality evidence).
- Optimized bismuth quadruple therapy includes appropriately dosed PPI, bismuth, nitroimidazole (1,500–2,000 mg in divided doses), and tetracycline (not doxycycline).
- All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 weeks after completion of therapy.
DOI: 10.14309/ajg.0000000000002968
View source ↗